Average rating: | Rated 4.5 of 5. |
Level of importance: | Rated 4 of 5. |
Level of validity: | Rated 4 of 5. |
Level of completeness: | Rated 4 of 5. |
Level of comprehensibility: | Rated 5 of 5. |
Competing interests: | None |
A short and well balanced account of the opportunitites and potential issues in supporting repurposing of approved drugs by state-of-the-art diagnostic approaches, including the use of multiomics and AI-based data interpretation. I miss a statement or small paragraph about the need for assay validation, batch-to-batch control, analyte stability, particularly when different patient populations are compared (issues with assay parallelity) in the endeavor to rationalize drug re-purposing. In addition, commenting on the validation of AI algorithms when clincal decisions are being taken and patient selection is being supported would ass value to the paper.